At the time of writing, Sarepta Therapeutics Inc [SRPT] stock is trading at $43.01, up 9.69%. An important factor to consider is whether the stock is rising or falling in short-term value. The SRPT shares have gain 14.39% over the last week, with a monthly amount glided 17.13%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sarepta Therapeutics Inc [NASDAQ: SRPT] stock has seen the most recent analyst activity on June 06, 2025, when Scotiabank upgraded its rating to a Sector Outperform. Previously, Evercore ISI downgraded its rating to In-line on May 08, 2025, and kept the price target unchanged to $50. On April 11, 2025, Wells Fargo initiated with a Overweight rating and assigned a price target of $115 on the stock. H.C. Wainwright upgraded its rating to a Neutral but stick to its price target of $75 on April 02, 2025. RBC Capital Mkts downgraded its rating to a Sector Perform and reduced its price target to $87 on March 31, 2025. Deutsche Bank started tracking with a Hold rating for this stock on February 11, 2025, and assigned it a price target of $136. In a note dated November 27, 2024, Needham reiterated an Buy rating on this stock and revised its target price from $205 to $202.
For the past year, the stock price of Sarepta Therapeutics Inc fluctuated between $34.10 and $173.25. Currently, Wall Street analysts expect the stock to reach $110 within the next 12 months. Sarepta Therapeutics Inc [NASDAQ: SRPT] shares were valued at $43.01 at the most recent close of the market. An investor can expect a potential return of 155.75% based on the average SRPT price forecast.
Analyzing the SRPT fundamentals
According to Sarepta Therapeutics Inc [NASDAQ:SRPT], the company’s sales were 2.23B for trailing twelve months, which represents an 80.15% jump. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at -0.07%, and Net Profit Margin reading is -0.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.2 and Total Capital is -0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.13 points at the first support level, and at 39.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 44.22, and for the 2nd resistance point, it is at 45.42.
Ratios To Look Out For
It is important to note that Sarepta Therapeutics Inc [NASDAQ:SRPT] has a current ratio of 4.02. On the other hand, the Quick Ratio is 2.46, and the Cash Ratio is 0.4. Considering the valuation of this stock, the price to sales ratio is 1.89, the price to book ratio is 3.70.
Transactions by insiders
Recent insider trading involved Nicaise Claude, Director, that happened on Mar 12 ’25 when 2491.0 shares were sold. Director, Nicaise Claude completed a deal on Mar 12 ’25 to buy 2491.0 shares. Meanwhile, Director Wigzell Hans Lennart Rudolf sold 10500.0 shares on Dec 12 ’24.
